Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.38 |
| ▸ | SI | P14410 | 1/20 | 0.38 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL473534 | 0.85 | MKNK2 (0.56) | RPS6KA5MAPTRAB9AESR1MKNK2 | |
| SCHEMBL473473 | 0.83 | RPS6KA5 (0.51) | RPS6KA5MAPTRAB9AESR1MKNK2 | |
| SCHEMBL16140670 | 0.75 | RPS6KA5 (0.67) | RPS6KA5MAPTMKNK2RPS6KA4MAPK1 | |
| SCHEMBL473484 | 0.73 | MAPK8 (0.64) | MKNK2ALDH1A1SMN1; SMN2KMT2ACYP2C9 | |
| SCHEMBL25881618 | 0.72 | RAB9A (0.42) | RAB9AMKNK2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL473490 | 0.72 | RAB9A (0.59) | RPS6KA5MAPTRAB9AMKNK2ALDH1A1 | |
| SCHEMBL5090434 | 0.71 | RPS6KA5 (0.68) | RPS6KA5MAPTMKNK2SMN1; SMN2KMT2A | |
| SCHEMBL24054006 | 0.69 | SMN1; SMN2 (0.48) | RPS6KA5MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL30166321 | 0.69 | SMN1; SMN2 (0.48) | RPS6KA5MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL25022126 | 0.69 | GAA (0.49) | MAPTRAB9AESR1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962622-B2 | Benzotriazole kinase modulators | ROCHE PALO ALTO LLC (US) | 2015-02-24 | — | — | US | disclosed |
| WO-2014155300-A2 | SUBSTITUED PYRIMIDINE AMINE DERIVATIVES AS TAK-1 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-10-02 | — | — | WO | disclosed |
| EP-2066319-B1 | BENZOTRIAZOLE KINASE MODULATORS | HOFFMANN LA ROCHE (CH) | 2012-02-01 | — | — | EP | disclosed |
| CN-101511359-A | Benzotriazole kinase modulators | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | CN | disclosed |
| EP-2066319-A1 | BENZOTRIAZOLE KINASE MODULATORS | F. Hoffmann-Roche AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| US-20080103142-A1 | Benzotriazole kinase modulators | ROCHE PALO ALTO LLC | 2008-05-01 | — | — | US | disclosed |
| WO-2008028860-A1 | BENZOTRIAZOLE KINASE MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103142-A1 | Benzotriazole kinase modulators | CDK1, CDK3, MAPK1 | RPS6KA5 344/4885MAPT 674/4885RAB9A 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.